Ann Lab Med 2019; 39(1): 113-113  https://doi.org/10.3343/alm.2019.39.1.113
Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea
Jeong Seong Yang, Kyung Jong Kim, Hongjo Choi, Seung Heon Lee
Department of R&D, Korean Institute of Tuberculosis, Cheongju, Korea
Published online: January 1, 2019.
© Korean Society for Laboratory Medicine. All rights reserved.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
This erratum is being published to correct the company errors on the article “Delamanid, Bedaquiline, and Line zolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resis tant and Extensively Drug-resistant Tuberculosis in Korea” Ann Lab Med 2018;38(6):563-8 https://doi.org/10.3343/alm.2018.38.6.563

Before correction:
Page 564:
2. Anti-TB drugs
Delamanid powder was obtained from Otsuka Pharmaceutical (Tokyo, Japan), bedaquiline powder was obtained from Janssen Pharmaceutica (Beerse, Belgium), and linezolid was supplied by Yungjin Pharmaceutical (Seoul, Korea).

After correction:
Page 564:
2. Anti-TB drugs
Delamanid powder was obtained from Otsuka Pharmaceutical (Tokyo, Japan) and Advanced ChemBlocks Inc (Burlingame, CA, USA). Bedaquiline powder was obtained from Janssen Pharmaceutica (Beerse, Belgium) and Advanced ChemBlocks Inc (Burlingame, CA, USA). Linezolid was supplied by Yungjin Pharmaceutical (Seoul, Korea).



This Article

e-submission

Archives

Indexed/Covered by